Peer-Reviewed Paper Introduces QRX003 and Its Mechanism of Action in Netherton SyndromeCase Report Details Professor Alan Irvine’s Clinical Experience Treating a Pediatric Patient Under Quoin’s Compassionate Use Program ASHBURN, Va., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that a manuscript titled “An Investigational Mechanism
– First-Ever Fast Track Designation Granted for a Peeling Skin Syndrome Therapy – Second Fast Track Designation Granted to QRX003, in Addition to Netherton Syndrome – Fast Track Designation Facilitates Development and Expedites Regulatory Review of Therapies Addressing Serious Conditions with Significant Unmet Medical Need – Follows July 2026 FDA Clearance of the First-Ever IND Submitted for Peeling Skin Syndrome – Phase 2/3 Study Expected to Initiate in 2H 2026, Enrolling up to 12 Pediatric and
This New Video Explores the Daily Realities of Raising a Child with Netherton Syndrome, and Its Impact on the Whole FamilyASHBURN, Va., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced the release of the latest episode in its NETHERTON NOW video series. This episode is about Aminah and is told by her adoptive mother, Laura Wright-Sext
Second Rare Pediatric Disease (RPD) Designation for QRX003FDA Previously Granted RPD Designation for QRX003 in Netherton SyndromeIf a New Drug Application (NDA) for QRX003 Is Approved for Peeling Skin Syndrome, Quoin May Receive a Freely Tradable Priority Review Voucher (PRV)Quoin Expects to Initiate Phase 2 Study in 2H 2026; Study Plans to Enroll up to 12 Pediatric and Adult Peeling Skin Patients in the U.S. and EuropeThere are Currently No Approved Treatments for Peeling Skin Syndrome ASHBURN,
Quoin has now received two rare paediatric disease designations for its lead asset QRX003.
Second Rare Pediatric Disease (RPD) Designation for QRX003FDA Previously Granted RPD Designation for QRX003 in Netherton SyndromeIf a New Drug Application (NDA) for QRX003 Is Approved for Peeling Skin Syndrome, Quoin May Receive a Freely Tradable Priority Review Voucher (PRV)Quoin Expects to Initiate Phase 2 Study in 2H 2026; Study Plans to Enroll up to 12 Pediatric and Adult Peeling Skin Patients in the U.S. and EuropeThere are Currently No Approved Treatments for Peeling Skin Syndrome ASHBURN,
ASHBURN, Va., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it has entered into a securities purchase agreement with new and existing healthcare-focused institutional investors to raise up to approximately $50.0 million in gross proceeds, including initial upfront funding of approximately $30.8 million and up to an additional a
Interim Analysis of the First Six Patients to Complete 12 Weeks of Treatment Met Pre-Specified Alpha Adjusted Target for Primary Endpoint with Statistical Significance Four of Six (66.7%) Participants Achieved the Target 1-Grade or Greater Improvement in Investigator Global Assessment at Week 12 (p=0.0087) With Statistical Significance versus the Pre-Specified Alpha of 0.0215Key Secondary Endpoint of Global Impression of Change Also Achieved Statistical Significance at Week 12 (p=0.0070) Versus
By M. Marin NASDAQ: QNRX READ THE FULL QNRX RESEARCH REPORT Among broadest development pipelines focused on rare dermatologic diseases, with three core markets identified – U.S., EU, Japan – & partnership sales network for ROW Quoin Pharmaceuticals (NASDAQ: QNRX), a late clinical stage, specialty pharmaceutical company focused on developing treatments for rare and orphan diseases, provided a
This is the newest page. Registered accounts read further back.